---
document_datetime: 2023-09-21 21:08:48
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps/starlix-epar-procedural-steps-taken-authorisation_en.pdf
document_name: starlix-epar-procedural-steps-taken-authorisation_en.pdf
version: success
processing_time: 0.3947367
conversion_datetime: 2025-12-30 21:50:51.056682
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## BACKGROUND INFORMATION ON THE PROCEDURE

## 1. Submission of the dossier

The applicant Novartis Europharm Ltd submitted on 22 December 1999 an application for Marketing Authorisation to the European Agency for the Evaluation of Medicinal Products (EMEA) for Starlix, through the centralised procedure. After agreement by the CPMP on 25 March 1999, this medicinal product has been referred to Part B of the Annex to Council Regulation No (EEC) 2309/93 of 22 July 1993 as amended.

The Rapporteur and Co-Rapporteur appointed by the CPMP were: Rapporteur: Dr. Mary Teeling                      Co-Rapporteur:        Prof. Cristina Sampaio Scientific Advice: The applicant  received  Scientific  Advice  from  the  CPMP  on  18  April  1996.  The  Scientific  Advice pertained to parts II and IV of the dossier. Licensing status: Starlix has been given a Marketing Authorisation in Japan in June 1999 under the name Fastic, Starsis. 2 Steps taken for the assessment of the product · The procedure started on 21 January 2000. · The Rapporteur's first Assessment Report was circulated to all CPMP members on 28 March 2000. The Co-Rapporteur's first Assessment Report was circulated to all CPMP members on 7 April 2000. · During the meeting on 23 May 2000 the CPMP agreed on the consolidated List of Questions to be sent to the applicant. The final consolidated List of Questions was sent to the company on 24 May 2000. · The  applicant  submitted  the  responses  to  the  CPMP  consolidated  List  of  Questions  on  10 August 2000. · The  summary  report  of  the inspection carried out  between  8-11  August  2000  at  the manufacturing site(s) of Novartis Pharma Stein AG, Shcaffhauser Strasse, CH-4332 Switzerland and Konapharma AG, Netzibodenstrasse 23-D, CH-4133 Prattein, Switzerland, was issued on 12 September 2000. · The Rapporteur circulated the response Assessment Report on the company's responses to the List of Questions to all CPMP members on 27 September 2000. · During  the  CPMP  meeting  on  12  December  2000,  outstanding  issues  were  addressed  by  the applicant during a hearing before the CPMP. · During  the  meeting  on  12-14  December  2000 the  CPMP,  in  the  light  of  the  overall  data submitted  and  the  scientific  discussion  within  the  Committee,  issued  a  positive  opinion  by majority vote for granting a Marketing Authorisation to Starlix on 14 December 2000. Medicinal Product no longer authorised